



MANAGEMENT

- Peter Lanciano
CEO
- Paul Hallenbeck, PhD
President & CSO
- John Neefe, MD
SVP, Clinical Development & Regulatory Affairs
- Scott Rakestraw, PhD
Business Development

BOARD OF DIRECTORS

- Peter Lanciano
CEO
- Matt Rieke, MD
Partner, Quaker BioVentures
- Sena Biswas, PhD
Managing Director, VIMAC Ventures
- Chris Kroeger, MD
Principal, Aurora Funds
- Dennis Panicali, PhD
*Former CEO & CSO
Therion Biologics*
- Paul Hallenbeck, PhD
President & CSO

SCIENTIFIC ADVISORS

- William Kaelin, Jr., MD
Dana-Farber Cancer Institute & Harvard Medical School
- John Minna, MD
Univ. of Texas Southwestern Medical Center, Dallas
- Vincent Racaniello, PhD
Columbia Univ. College of Physicians & Surgeons
- Jack Roth, MD
MD Anderson Cancer Center
- Charles Rudin, MD, PhD
John Hopkins Univ. - Sidney Kimmel Cancer Center
- Daniel Von Hoff, MD, FACP
Arizona Cancer Center

HIGHLIGHTS

- Developing highly targeted, naturally occurring oncolytic virus products
- Therapeutic agents can be systemically administered, and display a broad therapeutic window
- Phase I/II clinical program for NTX-010, a first-in-class anti-cancer agent
- Proprietary technology platform has identified multiple additional oncology product candidates now in pre-clinical development
- Experienced management team with a proven track record of healthcare business success
- Founded in 2003, now 24 employees
- Over 20 product and technology pending patents

PROFILE

Oncology company focused on first-in-class products

Neotropix is focused on the development of anti-cancer products that have a high degree of selectivity for tumor tissues resulting in both therapeutic efficacy and an excellent safety and tolerability profile. The products in development contain naturally occurring oncolytic viruses which have been discovered using the company’s proprietary technology platform. The therapeutic viruses selectively enter permissive cancer cells on the basis of a specific mechanism of tropism involving cell-surface receptors that are associated with transformed cancer cells.

Unlike other previous attempts to develop oncolytic virus agents, Neotropix’s therapeutic agents can be systemically administered to patients because (i) the agents are highly selective for cancer cells displaying tropic receptors; (ii) they have not been observed to be pathogenic to humans or animals; and (iii) humans lack pre-existing blood-borne antibodies which could neutralize the efficacy of the agents. In addition, pre-clinical and clinical studies to date indicate that the company’s therapeutic viruses are stable with respect to mutation, and no transmissibility from the patient to caregivers has been observed.

PIPELINE

PROGRAM	INDICATION	LEAD	PRE-CLINICAL	PHASE I	PHASE II
NTX-010	Small Cell Lung Cancer	→			
Program 2	Non-Small Cell Lung Cancer	→			
Program 3	Ovarian Cancer	→			
Program 4	Kidney Cancer	→			